In her latest research paper, published in the Journal of Molecular Neuroscience, Anne Robinson, Head of Carnegie Mellon’s Department of Chemical Engineering, explains why understanding the progression of neurodegeneration in Alzheimer’s disease, and its eventual treatment, is much more complex than researchers have previously thought.
One in ten Americans over the age of 65 suffer from Alzheimer’s, rising to one in three in those over 80. It is the sixth-leading cause of death in the United States, and more than…
